REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 41 04950 99066 02971 927--
Enterprise Value (EV)1 35 29150 09856 19663 21159 54557 653
P/E ratio 20,3x15,8x8,77x18,0x17,0x16,9x
Yield ------
Capitalization / Revenue 5,22x6,00x4,11x6,07x5,84x5,69x
EV / Revenue 4,49x5,90x3,50x5,34x4,84x4,56x
EV / EBITDA 10,3x11,8x5,71x10,6x9,07x8,35x
Price to Book 3,70x4,71x3,56x2,71x2,30x1,85x
Nbr of stocks (in thousands) 109 323105 544104 556107 746--
Reference price (USD) 375483632668668668
Announcement Date 02/06/202002/05/202102/04/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 7 8638 49716 07211 84412 31112 647
EBITDA1 3 4204 2459 8355 9446 5666 903
Operating profit (EBIT)1 2 2103 5778 9474 8995 1075 053
Operating Margin 28,1%42,1%55,7%41,4%41,5%40,0%
Pre-Tax Profit (EBT)1 2 4293 8109 3264 9685 1175 100
Net income1 2 1163 5138 0754 0404 1634 092
Net margin 26,9%41,3%50,2%34,1%33,8%32,4%
EPS2 18,530,572,037,139,239,6
Dividend per Share2 ------
Announcement Date 02/06/202002/05/202102/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 3 4534 9522 9652 8172 9692 970
EBITDA1 2 0572 9031 5281 3031 3871 343
Operating profit (EBIT)1 1 8472 6401 2871 2221 2501 276
Operating Margin 53,5%53,3%43,4%43,4%42,1%43,0%
Pre-Tax Profit (EBT)1 1 8172 5031 0611 2411 3261 359
Net income1 1 6322 229974923968961
Net margin 47,3%45,0%32,8%32,8%32,6%32,4%
EPS2 14,319,78,619,069,728,60
Dividend per Share ------
Announcement Date 11/04/202102/04/202205/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 5 7578919 8338 71612 38214 274
Leverage (Debt / EBITDA) -1,68x-0,21x-1,00x-1,47x-1,89x-2,07x
Free Cash Flow1 2 0002 0046 5296 5585 2435 465
ROE (Net Profit / Equities) 28,5%33,2%54,2%23,2%20,3%17,8%
Shareholders' equity1 7 42710 59514 89717 44820 49622 940
ROA (Net Profit / Asset) 15,9%22,0%37,9%16,2%15,7%13,9%
Assets1 13 27015 98421 29924 89726 45529 388
Book Value Per Share2 102102178247290361
Cash Flow per Share2 21,222,763,165,245,951,2
Capex1 430615552607619630
Capex / Sales 5,46%7,23%3,43%5,13%5,03%4,98%
Announcement Date 02/06/202002/05/202102/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 71 927 049 266
Net sales (USD) 16 071 700 000
Number of employees 10 492
Sales / Employee (USD) 1 531 805
Free-Float 81,0%
Free-Float capitalization (USD) 58 257 397 108
Avg. Exchange 20 sessions (USD) 453 314 495
Average Daily Capital Traded 0,63%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA